免疫细胞追踪难以靶向的脑肿瘤。
Immune cells track hard-to-target brain tumours.
出版信息
Nature. 2019 Jan;565(7738):170-171. doi: 10.1038/d41586-018-07728-9.
Abstract
Clinical trials reveal that personalized vaccines can boost immune-cell responses to brain tumours that don’t usually respond to immunotherapy. The findings also point to how to improve such treatments.
摘要
临床试验表明，个性化疫苗可以增强对通常对免疫疗法没有反应的脑肿瘤的免疫细胞反应。这些发现还指出了如何改进此类治疗方法。
相似文献
1
Immune cells track hard-to-target brain tumours.免疫细胞追踪难以靶向的脑肿瘤。
Nature. 2019 Jan;565(7738):170-171. doi: 10.1038/d41586-018-07728-9.
2
Progress in the fight against brain cancer.
Nature. 2019 Jan;565(7738):134. doi: 10.1038/d41586-019-00077-1.
3
Labeling T Cells to Track Immune Response to Immunotherapy in Glioblastoma.对胶质母细胞瘤免疫治疗中免疫反应进行 T 细胞标记。
Tomography. 2023 Jan 30;9(1):274-284. doi: 10.3390/tomography9010022.
4
IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.白细胞介素-21 增强同种异体人 Vγ9Vδ2 T 细胞对原发性脑胶质瘤肿瘤的反应性。
J Immunother. 2018 Jun;41(5):224-231. doi: 10.1097/CJI.0000000000000225.
5
Harnessing the immune system in glioblastoma.利用免疫系统治疗胶质母细胞瘤。
Br J Cancer. 2018 Nov;119(10):1171-1181. doi: 10.1038/s41416-018-0258-8. Epub 2018 Nov 5.
6
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.胶质母细胞瘤免疫治疗的转化图谱：用基础科学证据指导临床实践。
J Hematol Oncol. 2022 Jun 11;15(1):80. doi: 10.1186/s13045-022-01298-0.
7
Targeting EGFRvIII for glioblastoma multiforme.针对多形性胶质母细胞瘤的表皮生长因子受体III型变异体（EGFRvIII）
Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23.
8
T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.胶质母细胞瘤中的 T 细胞耗竭：免疫检查点的复杂性。
Trends Immunol. 2017 Feb;38(2):104-115. doi: 10.1016/j.it.2016.11.005. Epub 2016 Dec 7.
9
Skull bones harbour immune cells that are poised to target brain tumours.颅骨中含有随时准备靶向脑肿瘤的免疫细胞。
Nature. 2024 Sep;633(8030):528-529. doi: 10.1038/d41586-024-02789-5.
10
Emerging immunotherapies for glioblastoma.胶质母细胞瘤的新兴免疫疗法。
Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643.
引用本文的文献
1
Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review).低甲基化剂在胶质母细胞瘤治疗中的新兴应用（综述）
Mol Clin Oncol. 2024 Jun 28;21(3):59. doi: 10.3892/mco.2024.2757. eCollection 2024 Sep.
2
Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.通过负选择和外周耐受观察到的癌症新抗原：癌症疫苗的新途径。
J Clin Invest. 2024 Mar 1;134(5):e176740. doi: 10.1172/JCI176740.
3
Neoantigens: promising targets for cancer therapy.肿瘤新抗原：癌症治疗的有前途的靶点。
Signal Transduct Target Ther. 2023 Jan 6;8(1):9. doi: 10.1038/s41392-022-01270-x.
4
Comprehensive Analysis of as a Prognostic Biomarker and Its Association With Immune Infiltration in Glioma.作为胶质瘤预后生物标志物的综合分析及其与免疫浸润的关联
Front Oncol. 2022 May 12;12:896433. doi: 10.3389/fonc.2022.896433. eCollection 2022.
5
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.头颈部鳞状细胞癌患者肿瘤微环境的高度多重数字空间分析
Front Oncol. 2021 Jan 19;10:607349. doi: 10.3389/fonc.2020.607349. eCollection 2020.
6
Fluorine assembly nanocluster breaks the shackles of immunosuppression to turn the cold tumor hot.氟组装纳米团簇打破免疫抑制束缚，使冷肿瘤变热。
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):32962-32969. doi: 10.1073/pnas.2011297117. Epub 2020 Dec 14.
7
Opportunities for Antigen Discovery in Metastatic Breast Cancer.转移性乳腺癌中的抗原发现机会。
Front Immunol. 2020 Oct 30;11:570049. doi: 10.3389/fimmu.2020.570049. eCollection 2020.
8
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.基于计算机的结构建模在预测癌症疫苗开发的免疫原性新表位中的作用。
JCI Insight. 2020 Sep 3;5(17):136991. doi: 10.1172/jci.insight.136991.
9
Hypoxic Roadmap of Glioblastoma-Learning about Directions and Distances in the Brain Tumor Environment.胶质母细胞瘤的缺氧路线图——了解脑肿瘤环境中的方向和距离
Cancers (Basel). 2020 May 13;12(5):1213. doi: 10.3390/cancers12051213.
10
HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM).HSP70/IL-2 处理的 NK 细胞可有效穿透血脑屏障，并在诱导性多形性胶质母细胞瘤（GBM）大鼠模型中靶向肿瘤细胞。
Int J Mol Sci. 2020 Mar 25;21(7):2263. doi: 10.3390/ijms21072263.
本文引用的文献
1
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.基于 STING 的新抗原靶向疫苗与检查点调节剂联合增强了小鼠胰腺癌的抗肿瘤免疫。
JCI Insight. 2018 Oct 18;3(20):122857. doi: 10.1172/jci.insight.122857.
2
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.癌症免疫治疗中联合检查点调节剂的新兴策略。
J Clin Invest. 2018 Aug 1;128(8):3209-3218. doi: 10.1172/JCI120775.
3
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病中 CD19 嵌合抗原受体 (CAR) T 细胞治疗应答和耐药的决定因素。
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
4
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
5
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
6
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
7
An immunogenic personal neoantigen vaccine for patients with melanoma.一种用于黑色素瘤患者的免疫原性个人新抗原疫苗。
Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
8
Targeting neoantigens to augment antitumour immunity.靶向新抗原以增强抗肿瘤免疫力。
Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24.
Zotero 插件